

**Berkley Life Sciences**

200 PrincetonSouth Corporate Center, Suite 250  
Ewing, NJ 08628  
609-844.7800

**NEWS RELEASE**

**FOR IMMEDIATE RELEASE**

**MEDIA CONTACT:** Eric M. Jacobs  
Vice President  
609.844.7800

**Berkley Life Sciences Offers LS Prime<sup>®</sup> Corporate Lifeline<sup>™</sup> - an Innovative Foreign Corrupt Practices Act Insurance Expense Coverage for Life Science Companies**

**Ewing, NJ, February 10, 2015 -- Berkley Life Sciences, a W. R. Berkley Company,** today introduced Corporate Lifeline<sup>™</sup>, an essential new coverage for life science companies seeking to effectively address increased government scrutiny of company practices under the Foreign Corrupt Practices Act.

In 2009 the Criminal Division of the U.S. Department of Justice warned that “in the months and years ahead,” the Department would focus on “the application of the Foreign Corrupt Practices Act to the pharmaceutical industry.” Since that time the DOJ, and the Securities and Exchange Commission on the civil side, have kept this promise. Numerous life science companies and their executives have come under the enforcement microscope, requiring them to incur significant costs to respond to FCPA governmental inquiries into both their business activities and recordkeeping practices. These costs often are incurred even where no prosecution has been initiated, or claim against a company made.

Integrated with Berkley Life Sciences’ comprehensive and forward-thinking LS Prime<sup>®</sup> liability policy, Corporate Lifeline<sup>™</sup> addresses the pre-claim and other expenses associated with an FCPA inquiry or investigation. These costs are not addressed by the typical general liability policy issued to life science company clients, or even by many directors and officers policies.

Losses addressed by Corporate Lifeline<sup>™</sup> include not only the costs to defend against an FCPA proceeding, but also pre-suit response costs, such as certain pre-suit legal advisory expenses, and even certain self-reporting costs. The expenses incurred to seek the release of an executive or employee from foreign confinement are also part of the coverage.

Commenting on this new coverage, Jill Wadlund, President of Berkley Life Sciences, stated: “Pharmaceutical, medical device and biotech companies confront unique FCPA risks, chiefly due to significant levels of government interaction and approval during nearly every stage of business. Of additional significance is that the definition of a government official under the FCPA could include health care providers employed by state owned entities such as government run hospitals in foreign countries. Corporate Lifeline<sup>™</sup> has been carefully tailored to assist customers when they need help the most – when first contacted by the government, or when internal inquiry suggests that self-reporting is the best option to avoid or mitigate potential hefty civil and criminal penalties and reputational damage associated with an FCPA violation.”

Corporate Lifeline<sup>™</sup> is the most recent addition to the full array of insurance products developed by Berkley Life Sciences to address the unique needs of life sciences customers of all sizes. Products now offered by Berkley Life Sciences include commercial general liability; products and clinical trial liability; professional liability; commercial excess coverage; commercial package; inland marine; automobile; worker’s compensation; and umbrella. Through W. R. Berkley Syndicate 1967 at Lloyd’s, Berkley Life Sciences is also able to secure locally accepted insurance coverage around the world for its U.S. life science clients.

Life science firms – from start-up research entities to industry-leading manufacturers and service organizations – will benefit from Berkley Life Sciences’ comprehensive offerings and international capabilities, and the financial security of A+ admitted paper.

## **About Berkley Life Sciences**

Berkley Life Sciences, a member company of W. R. Berkley Corporation, is solely dedicated to serving the needs of the life science industry, providing sophisticated, innovative insurance products and services to life science customers of all sizes. For more information about Berkley Life Sciences, visit our website at [www.berkeleyls.com](http://www.berkeleyls.com).

Products and services are provided by one or more insurance company subsidiaries of W. R. Berkley Corporation. Not all products and services are available in every jurisdiction, and the precise coverage afforded by any insurer is subject to the actual terms and conditions of the policies as issued. Certain coverages may be provided through surplus lines insurance company subsidiaries of W. R. Berkley Corporation through licensed surplus lines brokers. Surplus lines insurers do not generally participate in state guaranty funds and insureds are therefore not protected by such funds.